[Detection of circulating activated platelets by anti-GMP-140 monoclonal antibodies].
The clinical significance and detection methods for circulating activated platelets are reviewed. It has been recently demonstrated that three kinds of platelet granules, dense granule, alpha-granule and lysosome, have specific membrane proteins; granulophysin, GMP-140 (PADGEM) and CD63 antigen, respectively, and that these specific granule-membrane proteins become exposed on the surface of the activated platelets. It is believed that detection of circulating activated platelets, using monoclonal antibodies specific to these granule-membrane, may be reliable and diagnostic value in thrombotic and prethrombotic diseases. Preliminary clinical studies using 2T60, a newly developed anti-GMP-140 monoclonal antibody, was presented.
Tanoue
K
K
Dept. of Cardiovascular Res., Tokyo Metropolitan Inst. of Medical Science.
Akamatsu
N
N
Suzuki
H
H
Katagiri
Y
Y
Yamazaki
H
H
Fujimoto
T
T
Fukuda
S
S
Onozawa
Y
Y
D000911:Antibodies, Monoclonal; D001665:Binding Sites; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D019007:P-Selectin; D015539:Platelet Activation; D010980:Platelet Membrane Glycoproteins / Q000032:analysis / Q000276:immunology* / Q000378:metabolism; D013927:Thrombosis / Q000175:diagnosis
D000911:Antibodies, Monoclonal; D019007:P-Selectin; D010980:Platelet Membrane Glycoproteins; D005340:Fibrinogen